Wednesday, 28 December 2011

AMRI restructures for 2012

AMRI is to take additional actions to streamline its operations in 2012. During Q4 2011 AMRI has reduced its workforce, reduced capacity and reduced operating costs. The company hopes these actions "will better align the business to current and expected market conditions and are expected to improve the company’s overall cost competitiveness and increase cash flow generation". AMRI said the reduction will primarily affect its US operations and will terminate the lease of one of its US facilities. AMRI expects that these cost-reduction initiatives will result save $10-11m per year.
Times Union

Angel Biotechnology has raised £1.15m through a placing of new shares

The Scotsman

Sunday, 18 December 2011

Cambrex's manufacturing site in Charles City, Iowa, has received a GMP certificate from the UK's Medicines and Healthcare products Regulatory Agency


Angel Biotechnology has signed a Framework Agreement to develop, scale up and manufacture a recombinant protein product for TransGenRx

RTT News

GE and M+W to build biopharma manufacturing plants

GE Healthcare and M+W Group have formed a partnership to offer an integrated, "turn-key" approach for the construction of biopharmaceutical manufacturing plants, to help meet the rapidly increasing worldwide demand for these potentially life-saving treatments. The alliance is targeted at emerging countries.
Bloomberg BusinessWeek

Lonza expands early phase manufacturing in China

Lonza has completed the expansion of it snarly phase manufacturing capacity in Nansha, China. Lonza has added a new cGMP kilo-lab and an additional small scale train to meet the growing demands of its global small molecule customers.
Manufacturing Chemist

Tuesday, 13 December 2011

DSM Pharmaceutical Products will manufacture and supply QRxPharma's MoxDuo morphine and oxycodone capsules for the US market through 2015

PR Newswire

EMA and FDA to collaborate on GMP inspections

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are to share work on inspections of manufacturing sites in each other's territories, starting in January 2012. The initiative builds on a pilot programme which ran earlier this year. Initially the programme will focus on inspections of manufacturing sites in the EU or US that are already known to the two authorities and have a history of compliance with GMP following previous inspections.

Australian biologics facility moves closer

DSM Biologics and the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) have signed a memorandum of understanding to construct and run Australia’s largest biologics scale-up facility in Brisbane. The Aus$65m facility, which is currently under construction, will be owned by Biopharmaceuticals Australia and will be run by DSM Biologics. The AIBN will collaborate on early stage biologics development.
Australian Life Scientist

Lonza is one of a number of companies receiving a share of £8.5m to address challenges in the development of cell based medicines

PM Live

IMCD has acquired Organotec

In-pharma Technologist

Wednesday, 7 December 2011

Novasep restructures balance sheet

Novasep has completed a restructuring of its balance sheet with its creditors. Additionally the French Fonds Stratégigue d’Investissement (French Strategic Investment Fund) has become a new investor in the company, which as abandoned its plans to merge with Minakem.
Speciality Chemicals

A UK court has found for Albemarle in a case against AstraZeneca regarding a clause in a supply agreement

Supply Management

Tuesday, 6 December 2011

Shasun aims for growth

Shasun Pharmaceuticals Managing Director S Abhaya Kumar has said the company aims to double its annual revenues to $389m, within four years, by increasing exports. The company is currently adding new API manufacturing capacity in Vizag, India, and expanding capacity in Newcastle, UK.
Economic Times

Thursday, 1 December 2011

Vivimed acquires Uquifa

Vivimed Labs has acquired Yule Catto's Uquifa pharmaceutical ingredients business for £35m. Uquifa operates three manufacturing sites, two in Spain and one in Mexico. Mark Robbins will remain CEO of Uquifa. Vivimed said the acquisition would strengthen its current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa.
Economic Times

Lonza will manufacture the API for Elan's ELND005

Pharmaceutical Business Review